NCT05559879 2026-04-15
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04774419 2026-02-03
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT07115927 2025-08-19
RODEO
University College, London
Phase 2 Not yet recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT05728814 2024-02-23
DORA
Grupo Español de Investigación en Cáncer de Ovario
Unknown
NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown